MaxCyte Presents Data on Stable Cell Line Generation and Rapid, High Titer Production of Antibodies and Proteins Using Flow Electroporation

Poster presentations at BPI’s Antibody Engineering & Therapeutics Meeting highlight high titer bioproduction capabilities of the MaxCyte STX® and MaxCyte VLX™ for Multiple Protein Types

Antibody Engineering 2013

GAITHERSBURG, Md.--()--MaxCyte®, Inc., the pioneer in scalable, high-performance cell transfection systems, will be presenting data demonstrating dramatic reductions in antibody development timelines by enabling large-scale transient gene expression directly within cells commonly used in commercial protein production. The presentation will be made at IBC’s 24th Annual Antibody Engineering and Therapeutics Meeting, held December 8-12, 2013 at the Hyatt Regency Huntington Beach Resort & Spa, CA.

The two posters — Antibody Development to Bioproduction Using CHO Transient Gene Expression: Gram/Liter Antibody Titers and Rapid Generation of High Yield, Stable Cell Lines via Flow Electroporation and Universal, Fully Scalable Transfection Platform for Production of Complex or Difficult-to-Express Proteins: Superior Performance over Other Transfection Methods & Expression Systems—will show the application of flow electroporation in high-efficiency, rapid generation of stable cell lines as well as the universality of flow electroporation for the rapid, high titer production of antibodies and other proteins such as bi-specific antibodies, recombinant proteins, VLPs, and viral vectors.

MaxCyte scientists will be available throughout the conference at Booth #505 for one-on one discussions about the technical details of flow electroporation for large-scale transient gene expression and rapid stable cell line generation as well as demonstrations of the MaxCyte STX® and MaxCyte VLX™.

“MaxCyte’s technology provides a rapid, reliable, and cost effective platform for production of multi-gram quantities of antibodies and other proteins from the earliest stages of development, characterization, and screening to a final production process,” says Douglas Doerfler, President and CEO of MaxCyte. “We’re excited to present data that shows the unparalleled effectiveness of the MaxCyte technology for production of a broad range of proteins in meaningful cell substrates as well as the platform’s unique capability for dramatically improving the speed and efficiency of stable cell line production.”

“MaxCyte flow electroporation is a unifying technology that simplifies product and process development from the bench to biomanufacturing,” says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. “Scalable transfection performance and protein expression are maintained over a range of microliters to hundreds of liters of culture. This combination of performance, flexibility, and scalability truly sets MaxCyte flow electroporation apart from other transfection methods.”

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed a portfolio of products including the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System, ideal tools for use in drug discovery research and screening and protein production environments. These products provide for the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, for rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.

For more information, http://www.maxcyte.com.

Contacts

MaxCyte, Inc.
Meg Duskin
Marketing Communications Manager
301-944-1645
mduskin@maxcyte.com

Sharing

Contacts

MaxCyte, Inc.
Meg Duskin
Marketing Communications Manager
301-944-1645
mduskin@maxcyte.com